The Procter & Gamble Company (PG)[Tv]

Key Developments

• Procter & Gamble completed the $3.8 billion acquisition of Thorne HealthTech, marking a transformative strategic pivot into the high-growth science-driven wellness and longevity sector—a clear departure from its legacy consumer staples identity.
• PG issued fiscal 2027 guidance highlighting $1 billion in after-tax headwinds from raw materials, energy, transportation, and interest costs—equivalent to a $0.56 EPS drag—while organic sales remain flat, driven solely by pricing, not volume growth.
• PG reported its fiscal Q4 earnings on July 29, 2026, amid a projected 4.7% decline in EPS despite modest revenue growth, signaling deepening margin pressures and weakening earnings momentum.
• PG maintained its 70-year streak of consecutive dividend increases with a 3% raise in April, reaffirming its status as a "Dividend King" amid persistent market skepticism over growth potential.
• PG announced a strategic manufacturing expansion in Egypt, representing a high-stakes pivot toward emerging market growth and supply chain resilience, positioning it for long-term revenue and margin expansion—though execution risk remains elevated.